Epigral Valuation Multiples

Epigral is valued at $429M as of October 2026, a 1.7x revenue multiple. In the last 12 months, Epigral revenue was $290M and Epigral EBITDA was $62M.

Epigral Overview

About Epigral

Epigral, formerly Meghmani Finechem, makes caustic soda, chlorine derivatives, and chloromethanes for industrial users such as pharma, agro and water treatment. Plants are in Dahej, Gujarat. It is headquartered in Ahmedabad.


Founded

2007

HQ

India

Employees

1.1K

Sectors

Financials (LTM)

Revenue: $290M
EBITDA: $62M

EV

$489M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Epigral Financials

Epigral reported last 12-month revenue of $290M and EBITDA of $62M.

In the same LTM period, Epigral generated $62M in EBITDA and $33M in net income.


Epigral P&L

In the most recent fiscal year, Epigral reported revenue of $264M and EBITDA of $59M.

Epigral is profitable as of last fiscal year, with gross margin of 40%, EBITDA margin of 22%, and net margin of 13%.

See analyst estimates for Epigral
LTMLast FY202320242025202620272028
Revenue$290M$264M$207M$249M$264M
Gross Profit-$106M$88M$108M$108M
Gross Margin-40%43%43%41%
EBITDA$62M$59M$56M$69M$63M
EBITDA Margin22%22%27%28%24%
EBIT Margin14%16%21%22%18%
Net Profit$33M$35M$25M$34M$36M
Net Margin11%13%12%13%14%
Net Debt-$60M---

Financial data powered by Morningstar, Inc.

Epigral Stock Performance

Epigral has current market cap of $429M, and enterprise value of $489M.


Epigral's stock price is $9.95.

Epigral share price decreased by 6.0% in the last 30 days, and by 47.8% in the last year.

Epigral has an EPS (earnings per share) of $0.81.

See more trading valuation data for Epigral
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$489M$429M-3.7%-6.0%-12.6%-47.8%$0.81

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Epigral Valuation Multiples

Epigral trades at 1.7x EV/Revenue multiple, and 7.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Epigral

Epigral Financial Valuation Multiples

As of October 22, 2026, Epigral has market cap of $429M and EV of $489M.

Epigral has a P/E ratio of 13.0x.

LTMLast FY202320242025202620272028
EV/Revenue1.7x1.9x2.4x2.0x1.9x
EV/EBITDA7.8x8.3x8.8x7.1x7.8x
EV/EBIT11.7x11.6x11.2x8.8x10.4x
EV/Gross Profit-4.6x5.5x4.5x4.5x
P/E13.0x12.2x17.3x12.8x12.0x
EV/FCF78.4xn/mn/m39.7x117.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Epigral Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Epigral Margins & Growth Rates

Epigral grew revenue by 17% and EBITDA by 10% in the last fiscal year.

In the most recent fiscal year, Epigral reported gross margin of 40%, EBITDA margin of 22%, and net margin of 13%.

See estimated margins and future growth rates for Epigral

Epigral Margins

Last FY202420252026202720282029
Gross Margin40%43%41%36%
EBITDA Margin22%28%24%21%
EBIT Margin16%22%18%14%
Net Margin13%13%14%11%
FCF Margin(0%)5%2%(0%)

Epigral Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth17%20%6%13%
Gross Profit Growth-23%0%(3%)
EBITDA Growth10%24%(9%)0%
EBIT Growth-27%(15%)(10%)
Net Profit Growth(10%)35%7%(9%)
FCF Growth-(775%)(66%)(119%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Epigral Operational KPIs

Epigral's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Epigral's Rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Epigral's Rule of X is 52% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Epigral
LTMLast FY202320242025202620272028
Rule of 4040%34%---
Bessemer Rule of X68%52%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue-1%1%2%1%
R&D Expenses to Revenue-0%0%0%0%
Opex to Revenue-24%21%21%23%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Epigral Competitors

Epigral competitors include GACL, Alok Indus, Yasho Industries, Vishnu Chemicals, Binh Minh Plastics, Rallis India, Intrepid Potash, Ashapura Minechem, AdvanSix and Prasol Chemicals.

Most Epigral public comparables operate across Chemicals.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
GACL$449M$51M1.1x-9.8x-
Alok Indus$385M($21M)711.1x-(13289.8x)-
Yasho Industries$85M$14M5.8x-34.2x-
Vishnu Chemicals$169M$28M2.8x-17.3x-
Binh Minh Plastics$213M$59M1.8x1.6x6.4x5.5x
Rallis India$303M$39M1.2x1.1x9.3x9.1x
Intrepid Potash$298M$50M0.8x0.9x4.8x3.6x
Ashapura Minechem$548M$72M1.0x-7.7x-

This data is available for Pro users. Sign up to see all Epigral competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Epigral

When was Epigral founded?Epigral was founded in 2007.
Where is Epigral headquartered?Epigral is headquartered in India.
How many employees does Epigral have?As of today, Epigral has over 1K employees.
Is Epigral publicly listed?Yes, Epigral is a public company listed on Bombay Stock Exchange.
What is the stock symbol of Epigral?Epigral trades under 543332 ticker.
When did Epigral go public?Epigral went public in 2021.
Who are competitors of Epigral?Epigral main competitors include GACL, Alok Indus, Yasho Industries, Vishnu Chemicals, Binh Minh Plastics, Rallis India, Intrepid Potash, Ashapura Minechem, AdvanSix, Prasol Chemicals.
What is the current market cap of Epigral?Epigral's current market cap is $429M.
What is the current revenue of Epigral?Epigral's last 12 months revenue is $290M.
What is the current revenue growth of Epigral?Epigral revenue growth (NTM/LTM) is 19%.
What is the current EV/Revenue multiple of Epigral?Current revenue multiple of Epigral is 1.7x.
What is the current EBITDA of Epigral?Epigral's last 12 months EBITDA is $62M.
What is Epigral's EBITDA margin?Epigral's last 12 months EBITDA margin is 22%.
What is the current EV/EBITDA multiple of Epigral?Current EBITDA multiple of Epigral is 7.8x.
What is the current FCF of Epigral?Epigral's last 12 months FCF is $6M.
What is Epigral's FCF margin?Epigral's last 12 months FCF margin is 2%.
What is the current EV/FCF multiple of Epigral?Current FCF multiple of Epigral is 78.4x.
How many companies Epigral has acquired to date?Epigral hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Epigral has invested to date?Epigral hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Epigral

Lists including Epigral

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial